Immutep (IMMP) Net Income towards Common Stockholders (2011 - 2025)

Immutep (IMMP) posted Net Income towards Common Stockholders of $64.9 million for Q4 2025, down 29.41% on a QoQ basis from $92.0 million in Q2 2025, and down 42.43% year-over-year from $112.8 million in Q4 2024.

Immutep (IMMP) Net Income towards Common Stockholders (2011 - 2025) Analysis & Trends

Immutep's Net Income towards Common Stockholders history runs 14 years deep, the most recent figure standing at $64.9 million for Q4 2025.

  • Quarterly Net Income towards Common Stockholders fell 42.43% year-over-year to $64.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $394.6 million (down 2.37% YoY) and the FY2025 annual result came in at $92.0 million, down 26.35% from the prior year.
  • Net Income towards Common Stockholders was $64.9 million for Q4 2025 at Immutep, down from $92.0 million in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at $124.9 million in Q2 2024 and bottomed at $50.4 million in Q4 2022.
  • A 5-year average of $81.5 million and a median of $77.3 million in 2021 frame the typical range for Net Income towards Common Stockholders.
  • Annual changes were most pronounced in 2021 — Net Income towards Common Stockholders jumped 158.52% — and 2025, when it slumped 42.43%.
  • Immutep's Net Income towards Common Stockholders stood at $79.3 million in 2021, then sank by 36.48% to $50.4 million in 2022, then soared by 49.41% to $75.3 million in 2023, then jumped by 49.82% to $112.8 million in 2024, then slumped by 42.43% to $64.9 million in 2025.
  • Business Quant data shows IMMP's Net Income towards Common Stockholders at $64.9 million in Q4 2025, $92.0 million in Q2 2025, and $112.8 million in Q4 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Oculis Holding AG 66,200.25 Bn 66,199.96 Bn - -625.73
2 Nanobiotix 1,908.00 Bn 1,907.94 Bn - -
3 Akari Therapeutics 959.56 Bn 959.56 Bn - -14.46 Mn
4 BeOne Medicines 471.75 Bn 466.96 Bn 1.35 Bn 227.36 Mn
5 Vertex Pharmaceuticals 121.94 Bn 114.69 Bn 2.59 Bn 1.03 Bn
6 Regeneron Pharmaceuticals 69.87 Bn 61.12 Bn 3.31 Bn 727.20 Mn
7 Belite Bio 62.43 Bn 62.43 Bn - -0.68
8 Argenx Se 55.86 Bn 50.68 Bn 1.41 Bn 472.00 Mn
9 Alnylam Pharmaceuticals 37.49 Bn 34.48 Bn 959.66 Mn 205.99 Mn
10 Immutep 559.62 Mn 559.62 Mn - 64.93 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 64.93 Mn
Jun 30, 2025 91.99 Mn
Dec 31, 2024 112.79 Mn
Jun 30, 2024 124.90 Mn
Dec 31, 2023 75.28 Mn
Jun 30, 2023 91.21 Mn
Dec 31, 2022 50.39 Mn
Jun 30, 2022 67.38 Mn
Dec 31, 2021 79.32 Mn
Jun 30, 2021 56.42 Mn
Dec 31, 2020 44.36 Mn
Jun 30, 2020 21.83 Mn
Dec 31, 2019 19.15 Mn
Jun 30, 2019 17.08 Mn
Dec 31, 2018 24.05 Mn
Jun 30, 2018 25.38 Mn
Jun 30, 2017 -2.31 Mn
Mar 31, 2017 -1.69 Mn
Dec 31, 2016 -3.10 Mn
Jun 30, 2016 -2.63 Mn